-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 28, 2022, the "RCT New Evidence for Antiplatelet Treatment of Ginkgolide Acute Ischemic Stroke" live broadcast satellite meeting, hosted by the Shanghai Stroke Society and co-organized by Chengdu Baiyu Pharmaceutical, was successfully concluded during the 3rd Annual Conference of the Shanghai Stroke Society
.
The conference was chaired by Professor Dong Qiang of Huashan Hospital affiliated to Fudan University, Professor Lou Min of the Second Affiliated Hospital of Zhejiang University School of Medicine, and Dr.
Dong Yi of Huashan Hospital affiliated to Fudan University as speakers, three neurologists and many neurologists in China gathered in the cloud to discuss the clinical exploration of antiplatelet therapy for acute ischemic stroke, and the cumulative number of viewers of the live broadcast reached more than 1830 people
.
The evidence-based evidence of the new RCT of ginkgolide was released under the joint witness of many experts and attracted the attention
of many neurologists in the industry.
At the beginning of the conference, Professor Dong Qiang of Shanghai Huashan Hospital affiliated to Fudan University delivered an opening speech, introducing the overview of two RCT trials of ginkgolide injection, affirming the efficacy of ginkgolide injection, and believing that its application in the acute phase of ischemic stroke has broad prospects and great prospects.
Dong Yi introduced the "Effectiveness of Ginkgolide in the Treatment of Acute Ischemic Stroke with Aortic Atherosclerosis", which included 936 cases and 61 centers, and Ginkgolide injection through the new pathway of PAF mechanism can effectively improve neurological defects and clinical outcomes in patients with acute ischemic stroke complicated with atherosclerosis, and the sooner it is used, the better
the prognosis.
Click on the video below to watch Dr.
Yi Dong's "Study on the effectiveness of ginkgolide in the treatment of acute ischemic stroke with atherosclerosis"
.
Focusing on "Current Status of Acute Stroke Reperfusion Treatment and Ginkgolide GIANT Test", Professor Lou introduced the indispensable advantages of Ginkgolide injection in acute stroke reperfusion treatment, and shared the medication experience and medication experience of Ginkgolide injection
.
Current status of reperfusion therapy for acute stroke
through a series of biochemical metabolic changes.
But for many years, there have been some obstacles to the clinical transformation of neuroprotection, from the early years of anti-free radicals, to uric acid, magnesium sulfate, to the combination of some immune agents, so far, no neuroprotective drug has been approved by the FDA for the treatment
of AIS.
GIANT trial interpretation GIANT is a clinical study on thrombolysis combined with neuroprotection, including 1113 ischemic stroke patients
in 24 centers.
The only natural molecular compound drug containing high-purity ginkgolide ABC and white fruit lactone
There is high-level evidence-based evidence throughout the course of ischemic stroke disease
.
The conference was chaired by Professor Dong Qiang of Huashan Hospital affiliated to Fudan University, Professor Lou Min of the Second Affiliated Hospital of Zhejiang University School of Medicine, and Dr.
Dong Yi of Huashan Hospital affiliated to Fudan University as speakers, three neurologists and many neurologists in China gathered in the cloud to discuss the clinical exploration of antiplatelet therapy for acute ischemic stroke, and the cumulative number of viewers of the live broadcast reached more than 1830 people
.
The evidence-based evidence of the new RCT of ginkgolide was released under the joint witness of many experts and attracted the attention
of many neurologists in the industry.
At the beginning of the conference, Professor Dong Qiang of Shanghai Huashan Hospital affiliated to Fudan University delivered an opening speech, introducing the overview of two RCT trials of ginkgolide injection, affirming the efficacy of ginkgolide injection, and believing that its application in the acute phase of ischemic stroke has broad prospects and great prospects.
Focus on clinical research
Ginkgolide effectively improves neurological deficits in stroke patients
In the first part of the conference, Dr.Dong Yi introduced the "Effectiveness of Ginkgolide in the Treatment of Acute Ischemic Stroke with Aortic Atherosclerosis", which included 936 cases and 61 centers, and Ginkgolide injection through the new pathway of PAF mechanism can effectively improve neurological defects and clinical outcomes in patients with acute ischemic stroke complicated with atherosclerosis, and the sooner it is used, the better
the prognosis.
Click on the video below to watch Dr.
Yi Dong's "Study on the effectiveness of ginkgolide in the treatment of acute ischemic stroke with atherosclerosis"
A study of the effectiveness of ginkgolide in the treatment of acute ischemic stroke complicated with atherosclerosis, published in CNS Neuroscience & Therapeutics in 2021
.
Interpreting the GIANT trial
Ginkgolide significantly improves clinical outcomes in stroke patients
In the second part of the conference, Professor Lou Min introduced in detail "Combination Therapy" of "Hyperacute Reperfusion Therapy for Cerebral Infarction".
Focusing on "Current Status of Acute Stroke Reperfusion Treatment and Ginkgolide GIANT Test", Professor Lou introduced the indispensable advantages of Ginkgolide injection in acute stroke reperfusion treatment, and shared the medication experience and medication experience of Ginkgolide injection
.
Click the video below to watch Professor Lou Min's "Combination Therapy" of Hyperacute Reperfusion Therapy for Cerebral Infarction
1.Current status of reperfusion therapy for acute stroke
At present, the most important treatment for ischemic thrombolysis is reperfusion therapy, including intravenous thrombolysis and mechanical thrombectomy, but nearly 50% of patients do not achieve good clinical outcomes
.
through a series of biochemical metabolic changes.
But for many years, there have been some obstacles to the clinical transformation of neuroprotection, from the early years of anti-free radicals, to uric acid, magnesium sulfate, to the combination of some immune agents, so far, no neuroprotective drug has been approved by the FDA for the treatment
of AIS.
In response to this situation, the Stroke Treatment Academic Industry Roundtable (STAIR) was established in the United States to regularly discuss clinical trial studies of acute ischemic stroke, and the strategy has begun to work
.
This strategy suggests that neuroprotective therapy needs to be combined with reperfusion therapy; After recirculation and reperfusion of blood flow, with neuroprotective agents, better results can be obtained; Neuroprotective agents are preferably drugs
with multi-target therapeutic effects.
During the entire chain reaction process, if only a certain point is targeted, effective protection may not be achieved
.
GIANT trial interpretation GIANT is a clinical study on thrombolysis combined with neuroprotection, including 1113 ischemic stroke patients
in 24 centers.
Trial methods: Randomized into 2 groups, the treatment group was ginkgolide injection treatment group, through 7 days of treatment, 3 months follow-up; The control group used normal saline
.
Observations: difference in NHISS scores at 24 hours; 7-day efficiency and safety results for NIHSS; At 90 days, the difference
in Rankin scores between the two groups.
GIANT test results
▼
1.
Ginkgolide injection significantly improved the clinical outcome of patients with acute ischemic stroke at 90 days;
2.
Ginkgolide injection effectively improves neurological function in the early treatment of acute ischemic stroke;
3.
On the basis of the standard treatment of acute ischemic stroke, the use of ginkgolide in the first 24 hours after IVT is safe, does not increase the risk of bleeding, and may improve the prognosis;
4.
Ginkgolide combined with alpeplase treatment may be the recommended treatment for patients in the first 24 hours after IVT.
The study was published in the journal Front Pharmacol in 2021
.
Introduction of ginkgolide injection
1.The only natural molecular compound drug containing high-purity ginkgolide ABC and white fruit lactone
Ginkgolide injection directly targets the clinical pain point and is the only natural molecular compound drug
containing high-purity ginkgolide ABC and white fruitolactone.
There is high-level evidence-based evidence throughout the course of ischemic stroke disease
Ginkgolide injection has high-level evidence-based evidence in the whole process of ischemic stroke disease, which is worthy of clinical promotion and application
.
New evidence from the Ginkgolide RCT provides a safe and effective new treatment for
acute ischaemic stroke.
Ginkgolide injection is an antiplatelet-binding neuroprotective, double-effect product, safe, effective, high pharmacoeconomic value, suitable for the whole treatment of ischemic stroke, worthy of high attention
of neurologists.
Expert profiles
Professor Dong Qiang
Professor, doctoral supervisor
Shanghai Leading Talents Top 10 Public Health Workers in Shanghai
Director of Department of Neurology, Huashan Hospital, Fudan University
Deputy Director of the National Medical Center for Neurological Diseases (Huashan).
Vice Chairman of the Neurology Branch of the Chinese Medical Association, Vice President of the Chinese Stroke Society
Chairman of the Neurology Committee of Shanghai Medical Association, President of the Neurologist Branch of Shanghai Medical Doctor Association
Director of Shanghai Clinical Medical Center for Neurological Diseases, Director of Shanghai Quality Control Center of Neurology
Executive Vice President of Shanghai Stroke Society
Professor Lou Min
Professor of Zhejiang University, chief physician, doctoral supervisor
Deputy Dean of Zhejiang University School of Medicine
Deputy Director of the Department of Neurology, The Second Affiliated Hospital of Zhejiang University School of Medicine
Deputy Director of the Institute of Brain Medicine, Zhejiang University
Director of the Chinese Stroke Society
Vice Chairman of the Medical Quality Branch of the Chinese Stroke Society
Member of the Cerebrovascular Group of the Neurology Branch of the Chinese Medical Association
Chairman-elect of the Neurology Branch of Zhejiang Medical Association
Vice Chairman of the Youth Committee of the Stroke Prevention and Control Project of the National Health and Family Planning Commission
Secretary General of Zhejiang Stroke Society
Dr.
Yi Dong
Doctor of Medicine, graduated from Fudan University, currently mainly responsible for the cerebrovascular fusion ward of Hongqiao Campus of Huashan Hospital affiliated to Fudan University
He has studied at OSF/INI Comprehensive Stroke Clinic in the United States and Oxford University in the United Kingdom
From 2018 to 2019, he was trained in the International Clinical Investigator Training Program at Harvard University
